Cationic Lipid Complex for siRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cationic lipids used for nucleic acid delivery, such as siRNA, face challenges in stability and penetration due to decomposition by ribonuclease in blood plasma and difficulty in crossing the cell membrane, and existing formulations have issues with aggregation during storage.
Innovation Solution
A novel cationic lipid compound, represented by specific Formulae, is developed, which forms a lipid complex with neutral lipids, polyethylene glycol-modified lipids, and sterols, enhancing stability and delivery efficiency by encapsulating nucleic acids and reducing aggregation through a specific synthesis process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If siRNA is encapsulated in fine particles containing cationic lipid, then protection from decomposition and cell membrane penetration are improved, but aggregation during storage occurs
Solution Approach 1:
The invention uses a composite lipid formulation combining cationic lipid (for nucleic acid binding and protection), PEG-modified lipid (for steric stabilization and aggregation prevention), and cholesterol (for membrane fusion enhancement). This multi-component composite resolves the contradiction by integrating materials with complementary functions that simultaneously provide protection and prevent aggregation.
Solution Approach 2:
PEG-modified lipid acts as an intermediary component that mediates between the cationic lipid-nucleic acid complex and the aqueous environment. The PEG chain provides steric repulsion that prevents aggregation while allowing the cationic lipid to maintain its protective function, thus resolving the contradiction through a mediating substance.
2Ease of operation
If cationic lipid is used to deliver nucleic acid, then cell membrane penetration is improved, but biodegradability is insufficient
Solution Approach 1:
The invention modifies the cationic lipid structure by introducing biodegradable linkages (such as ester bonds in the hydrocarbon chains) while maintaining the cationic head group functionality. This parameter change allows the lipid to retain its membrane penetration capability while becoming susceptible to enzymatic degradation, thus resolving the contradiction between penetration efficiency and biodegradability.
3Stability of the object's composition
If PEG lipid is added to suppress aggregation, then storage stability is improved, but nucleic acid delivery efficiency decreases
Solution Approach 1:
The invention optimizes the local concentration and distribution of PEG-lipid within the formulation, using it at controlled low percentages (0.1-10 mol%) specifically for surface stabilization. The cationic lipid remains the dominant component (70-90 mol%) to maintain nucleic acid binding and delivery efficiency, while the PEG-lipid provides localized aggregation prevention at the particle surface, thus resolving the contradiction through spatial and compositional optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cationic lipid complex efficiently releases nucleic acids into the cytoplasm, improving delivery efficacy and stability, while minimizing aggregation during storage, thus overcoming previous limitations in therapeutic applications.
Implementation Method 1
by encapsulating siRNA in a fine particle containing a cationic lipid, the encapsulated siRNA is protected from decomposition in blood plasma and can penetrate a lipophilic cell membrane
Implementation Method 2
a method of suppressing aggregation by allowing a polyethylene glycol-modified lipid (PEG lipid) to be contained in the fine particles
Data Source
AI summary
The present invention provides a cationic lipid which can be utilized for nucleic acid delivery into the cytoplasm. The cationic lipid of the present invention is, for example, a compound represented by the following Formula (1) or a pharmaceutically acceptable salt thereof.